- Home
- CANF vs EDSA Comparison
CANF vs EDSA Comparison
Compare CANF & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- EDSA
- Stock Information
- Founded
- CANF 1994
- EDSA 2015
- Country
- CANF Israel
- EDSA Canada
- Employees
- CANF N/A
- EDSA N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- EDSA Health Care
- Exchange
- CANF Nasdaq
- EDSA Nasdaq
- Market Cap
- CANF 14.8M
- EDSA 13.8M
- IPO Year
- CANF N/A
- EDSA N/A
- Fundamental
- Price
- CANF $1.03
- EDSA $2.05
- Analyst Decision
- CANF Strong Buy
- EDSA Strong Buy
- Analyst Count
- CANF 2
- EDSA 2
- Target Price
- CANF $14.00
- EDSA $13.00
- AVG Volume (30 Days)
- CANF 129.3K
- EDSA 33.4K
- Earning Date
- CANF 04-14-2025
- EDSA 08-08-2025
- Dividend Yield
- CANF N/A
- EDSA N/A
- EPS Growth
- CANF N/A
- EDSA N/A
- EPS
- CANF N/A
- EDSA N/A
- Revenue
- CANF $674,000.00
- EDSA N/A
- Revenue This Year
- CANF $461.72
- EDSA N/A
- Revenue Next Year
- CANF N/A
- EDSA N/A
- P/E Ratio
- CANF N/A
- EDSA N/A
- Revenue Growth
- CANF N/A
- EDSA N/A
- 52 Week Low
- CANF $0.98
- EDSA $1.55
- 52 Week High
- CANF $4.69
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- CANF 39.89
- EDSA 52.89
- Support Level
- CANF $1.02
- EDSA $1.91
- Resistance Level
- CANF $1.09
- EDSA $2.14
- Average True Range (ATR)
- CANF 0.04
- EDSA 0.12
- MACD
- CANF -0.00
- EDSA 0.02
- Stochastic Oscillator
- CANF 6.67
- EDSA 64.52
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.